サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ドラベ症候群治療の世界市場 - 成長率、将来の見通し、競合分析：2022年～2030年
市場調査レポート
商品コード
1176005

ドラベ症候群治療の世界市場 - 成長率、将来の見通し、競合分析：2022年～2030年

Dravet Syndrome Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 117 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ドラベ症候群治療の世界市場 - 成長率、将来の見通し、競合分析：2022年～2030年
出版日: 2022年08月10日
発行: Acute Market Reports
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のドラベ症候群治療の市場規模は、2021年に2億8,820万米ドルとなり、2022年～2030年の予測期間中にCAGRで11.7％の成長が予測されています。最近の治療薬の承認により、全体の市場規模が拡大し、大手製薬企業の注目を集めています。

当レポートでは、世界のドラベ症候群治療市場について調査分析し、市場力学、セグメント別の市場分析、地域別の市場分析、主要企業などについて、最新の情報を提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 ドラベ症候群治療市場：ビジネスの見通しと市場力学

  • イントロダクション
  • 世界のドラベ症候群治療市場金額（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因・抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
  • PESTEL分析

第4章 ドラベ症候群治療市場：医薬品別（2020年～2030年）

  • 市場概要
  • 成長率・収益分析：2021年 vs. 2030年
  • 市場セグメンテーション
    • トピラマート
    • レベチラセタム
    • ゾニサミド
    • バルプロ酸
    • クロバザム
    • クロンゼパム
    • スチリペントール
    • カンナビジオール

第5章 北米のドラベ症候群治療市場（2020年～2030年）

  • 市場概要
  • ドラベ症候群治療市場：医薬品別
  • ドラベ症候群治療市場：地域別
    • 北米

第6章 英国・欧州連合のドラベ症候群治療市場（2020年～2030年）

  • 市場概要
  • ドラベ症候群治療市場：医薬品別
  • ドラベ症候群治療市場：地域別
    • 英国・欧州連合

第7章 アジア太平洋地域のドラベ症候群治療市場（2020年～2030年）

  • 市場概要
  • ドラベ症候群治療市場：医薬品別
  • ドラベ症候群治療市場：地域別
    • アジア太平洋地域

第8章 ラテンアメリカのドラベ症候群治療市場（2020年～2030年）

  • 市場概要
  • ドラベ症候群治療市場：医薬品別
  • ドラベ症候群治療市場：地域別
    • ラテンアメリカ

第9章 中東・アフリカのドラベ症候群治療市場（2020年～2030年）

  • 市場概要
  • ドラベ症候群治療市場：医薬品別
  • ドラベ症候群治療市場：地域別
    • 中東・アフリカ

第10章 企業プロファイル

  • GW Pharmaceuticals Plc.
  • Ovid Therapeutics
  • PTC Therapeutics, Inc.
  • Epygenix Therapeutics, Inc.
  • Zogenix, Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Biocodex S.A.
  • OPKO Health Inc.
  • Biscayne Neurotherapeutics, Inc.
  • Stoke Therapeutics
  • Sage Therapeutics
  • Xenon Pharmaceuticals
図表

List of Tables

  • TABLE 1 Global Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
  • TABLE 2 North America Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
  • TABLE 5 Latin America Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Dravet Syndrome Treatment Market By Drugs, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Dravet Syndrome Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Dravet Syndrome Treatment Market: Quality Assurance
  • FIG. 5 Global Dravet Syndrome Treatment Market, By Drugs, 2021
  • FIG. 6 Global Dravet Syndrome Treatment Market, By Geography, 2021
  • FIG. 7 Global Dravet Syndrome Treatment Market, By Drugs, 2021 Vs 2030, %
  • FIG. 8 U.S. Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 France Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 China Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 India Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Dravet Syndrome Treatment Market (US$ Million), 2020 - 2030
目次
Product Code: 138720-08-22

Industry Outlook

Dravet syndrome treatment accounted for a market value of US$ 288.2 Mn in 2021 and projected to grow at a CAGR of 11.7% during the forecast period from 2022 to 2030. The current treatment options available for Dravet syndrome target specifically the symptomatic relief associated with epileptic seizures. However, recent drug approvals for Dravet syndrome treatment has increased the overall market size and attracted attention of major pharmaceutical companies. In June 2020, Epidiolex (Cannabidiol) from GW Pharmaceuticals approved by USFDA specifically for Dravet syndrome. Epidiolex was followed by Fintepla (Earlier ZX008) owned by Zogenix is under approval process in the U.S. & Europe, this announcement soared shares of Zogenix by 20.5% in March 2021. Thus, overall target specific drugs are entering in the Dravet syndrome treatment horizon due to which its market growth expected to spurt from 2022 to 2030.

Stiripentol and cannabidiol will assist the significant growth of Dravet syndrome treatment market throughout the forecast period

In August 2020, the U.S. Food and Drug Administration (FDA) had approved stiripentol brand named as Diacomit to treat seizures associated with Dravet syndrome. Stiripentol's market share is growing at significant rate post 2020 due to higher efficiency, safety and prolonged relief from seizures. In addition to that, cannabidiol brand named as Epidiolex manufactured by GW Research Ltd. approved in June 2020. Cannabidol is first FDA-approved drug that contains a purified drug substance derived from marijuana. Thus, overall environment of Dravet syndrome treatment market is growing significantly due to strong drug pipeline and recently approved drugs.

North America dominated the overall global market especially due to recent drug approvals and developed diagnostic technology

In 2021, North America dominated the market and expected to maintain its dominance throughout the forecast period due to key market drivers such as rising awareness related to neurological disorders, increasing demand for target-specific drugs to treat Dravet syndrome, and high accessibility & adaptability for recently launched drugs. During the forecast period from 2021 to 2029, Asia Pacific expected to grow significantly throughout the forecast period due to increasing awareness related to Dravet syndrome coupled with developing diagnostic technologies in neurological disease area.

The key market players involved in the Dravet syndrome treatment industry studied based on financial data, product portfolio, current press releases, and key market strategies. This report also covers attractive investment proposition analyzed based on exclusive geographical PESTEL analysis. Major companies included in the report are GW Pharmaceuticals Plc., Ovid Therapeutics, PTC Therapeutics, Inc., Epygenix Therapeutics, Inc., Zogenix, Inc., Takeda Pharmaceutical Company Ltd., Biocodex S.A., OPKO Health Inc., and Biscayne Neurotherapeutics, Inc. among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Dravet Syndrome Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Dravet Syndrome Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drugs

  • Topiramate
  • Levetiracetam
  • Zonisamide
  • Valproic Acid
  • Clobazam
  • Clonzepam
  • Stiripentol
  • Cannabidiol

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Dravet Syndrome Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Dravet Syndrome Treatment market?
  • Which is the largest regional market for Dravet Syndrome Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Dravet Syndrome Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Dravet Syndrome Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Dravet Syndrome Treatment Market
  • 2.2. Global Dravet Syndrome Treatment Market, By Drugs, 2021 (US$ Million)
  • 2.3. Global Dravet Syndrome Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Dravet Syndrome Treatment Market Vendors
    • 2.6.2. Strategies Adopted by Dravet Syndrome Treatment Market Vendors
    • 2.6.3. Key Industry Strategies

3. Dravet Syndrome Treatment Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Dravet Syndrome Treatment Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Topiramate
    • 4.3.2. Levetiracetam
    • 4.3.3. Zonisamide
    • 4.3.4. Valproic Acid
    • 4.3.5. Clobazam
    • 4.3.6. Clonzepam
    • 4.3.7. Stiripentol
    • 4.3.8. Cannabidiol

5. North America Dravet Syndrome Treatment Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
  • 5.3.Dravet Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Dravet Syndrome Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
  • 6.3.Dravet Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Dravet Syndrome Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
  • 7.3.Dravet Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Dravet Syndrome Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
  • 8.3.Dravet Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Dravet Syndrome Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Dravet Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
  • 9.3.Dravet Syndrome Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. GW Pharmaceuticals Plc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. Ovid Therapeutics
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. PTC Therapeutics, Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. Epygenix Therapeutics, Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. Zogenix, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. Takeda Pharmaceutical Company Ltd.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Biocodex S.A.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. OPKO Health Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Biscayne Neurotherapeutics, Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Stoke Therapeutics
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives
  • 10.11. Sage Therapeutics
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Portfolio
    • 10.11.4. Strategic Initiatives
  • 10.12. Xenon Pharmaceuticals
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Portfolio
    • 10.12.4. Strategic Initiatives